版本:
中国

BRIEF-Protagonist Therapeutics receives $1.34 mln SBIR funding for development of biomarkers

May 24 Protagonist Therapeutics Inc:

* Protagonist Therapeutics Inc - receives $1.34 million SBIR funding for development of biomarkers of il-23 receptor antagonist activity

* Protagonist Therapeutics Inc - company expects to initiate human clinical testing of PTG-200 in second half of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐